Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Meta‐analysis: The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease
Sonika Sethi, Shiluka Dias, Aditi Kumar, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 12, pp. 1362-1374
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 521-538
Open Access | Times Cited: 33
Challenges in IBD Research 2024: Precision Medicine
Sana Syed, Brigid S. Boland, Lauren T Bourke, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S39-S54
Open Access | Times Cited: 9
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
Thanaboon Chaemsupaphan, Rupert W. Leong, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1234-1243
Open Access | Times Cited: 8
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab
Rachel Porth, Tina Deyhim, Samantha Zullow, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 3
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease
Rachel Porth, Tina Deyhim, Grace Geeganage, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 3
Inflammatory Bowel Disease: From Conventional Immunosuppression to Biologic Therapy
Aleksandra Sokić-Milutinović, Tomica Milosavljević
Digestive Diseases (2023) Vol. 42, Iss. 4, pp. 325-335
Open Access | Times Cited: 8
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach
Devendra Desai
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 93-102
Closed Access | Times Cited: 2
The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study
Cynthia H. Seow, John K. Marshall, Erin Stewart, et al.
Journal of the Canadian Association of Gastroenterology (2024) Vol. 7, Iss. 4, pp. 290-298
Open Access | Times Cited: 2
Forecasted Infliximab Concentrations During Induction Predict Time to Remission and Sustained Disease Control of Inflammatory Bowel Disease
Séverine Vermeire, Marla C. Dubinsky, Shervin Rabizadeh, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 6, pp. 102374-102374
Closed Access | Times Cited: 2
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review
Zachary Green, R. Mark Beattie, James J. Ashton
Translational Pediatrics (2023) Vol. 12, Iss. 10, pp. 1853-1874
Open Access | Times Cited: 6
De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review
Javier P. Gisbert, María Chaparro
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 642-658
Closed Access | Times Cited: 6
Relationship Between Serum Ustekinumab Trough Concentration and Clinical and Biochemical Disease Activity: A Real-World Study in Adult Patients with Crohn’s Disease
Khue M. Nguyen, Vandita Y. Mattoo, Sara Vogrin, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2023) Vol. 48, Iss. 3, pp. 271-279
Closed Access | Times Cited: 5
A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
Sanket Patel, Andrés Yarur
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6577-6577
Open Access | Times Cited: 5
Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease
Tal Marshanski, Eliana Fanous, Noa Tal, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 3, pp. 564-572
Closed Access | Times Cited: 1
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial
Robert D. Little, Jo McKenzie, Ashish Srinivasan, et al.
BMJ Open (2024) Vol. 14, Iss. 7, pp. e081787-e081787
Open Access | Times Cited: 1
90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients
Pasqua Letizia Pesole, Marina Liso, Rossella Donghia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3955-3955
Open Access | Times Cited: 4
Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis
Samuel Fernandes, Sónia Bernardo, S Saraiva, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 11, pp. 1974-1982
Closed Access | Times Cited: 4
Therapeutic drug monitoring in inflammatory bowel disease: recent developments
Xavier Roblin, Robert D. Little, Nicolas Mathieu, et al.
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 10, pp. 575-586
Closed Access | Times Cited: 1
Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis
Dena Zeraatkar, Tyler Pitre, Sarah Kirsh, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000998-e000998
Open Access | Times Cited: 1
Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus
Yago González‐Lama, Elena Ricart, Daniel Carpio, et al.
BMJ Open Gastroenterology (2024) Vol. 11, Iss. 1, pp. e001246-e001246
Open Access
Page 1 - Next Page

Scroll to top